Article and Video CATEGORIES
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
Please Note: New Treatments Have Emerged Since this Original Post
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on